miR-198 inhibits the progression of renal cell carcinoma by targeting BIRC5
-
Published:2021-07-21
Issue:1
Volume:21
Page:
-
ISSN:1475-2867
-
Container-title:Cancer Cell International
-
language:en
-
Short-container-title:Cancer Cell Int
Author:
Yuan Chao, Su Zhenhong, Liao Shengjie, Li Duanzhuo, Zhou Zhiwen, Wang Yawen, Quan Mingchun, Zeng Lingling, Lv Cai, Shen Chenyi, Gong Weida, Wu Jianfeng, Chen Xiaogang, Hu Wenbing, Lv Xu, Si WenxiaORCID, Yu Xin
Abstract
Abstract
Background
miR-198 is involved in the formation, migration, invasion, and metastasis of various malignant cancers. However, the function and mechanism of action of miR-198 in the tumorigenesis of renal cell carcinoma (RCC) remain elusive. Here, we aimed to explore the role of miR198 in RCC.
Methods
Immunohistochemistry was performed to estimate the level of survivin in RCC sections. Quantitative real-time polymerase chain reaction was performed to determine the expression level of miR-198 in fresh RCC tissues. Furthermore, the target relationship between miR-198 and BIRC5 was predicted using the TargetScanHuman 7.2 database and verified via dual-luciferase reporter assay and western blotting. The effects of miR-198 on the viability, apoptosis, invasion, and migration of A498 and ACHN cells were studied using Cell Counting Kit-8, flow cytometry, transwell migration assay, and wound healing assay, respectively. Additionally, a xenograft nude mouse model was established to evaluate the effect of miR-198 on RCC tumorigenesis.
Results
The expression levels of BIRC5 and miR-198 were respectively higher and lower in RCC tissues than those in normal adjacent tissues. Furthermore, miR-198 could inhibit luciferase activity and reduce the protein level of survivin without affecting the BIRC5 mRNA levels. miR-198 inhibited cell viability, migration, and invasion and promoted cell apoptosis; co-transfection with BIRC5 could rescue these effects. Moreover, miR-198 could repress tumor growth in the xenograft nude mouse model of RCC.
Conclusions
Our study demonstrates that miR-198 suppresses RCC progression by targeting BIRC5.
Funder
the China National Natural Science Foundation young scholar grant Hubei Nature Science Foundation Huangshi Science and Technology Plan Project Hubei Polytechnic University School Talent introduction project natural science foundation of hubei province
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference26 articles.
1. Petejova, N, Martinek A. Renal cell carcinoma: review of etiology, pathophysiology and risk factors. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 2016;160:183–94. 2. Guo ZQ, Zheng T, Chen B, Luo C, Ouyang S, Gong S, Li J, Mao LL, Lian F, Yang Y, Huang Y, Li L, Lu J, Zhang B, Zhou L, Ding H, Gao Z, Zhou L, Li G, Zhou R, Chen K, Liu J, Wen Y, Gong L, Ke Y, Yang SD, Qiu XB, Zhang N, Ren J, Zhong D, Yang CG, Liu J, Jiang H. Small-molecule targeting of E3 Ligase adaptor SPOP in kidney cancer. Cancer Cell. 2016;30:474–84. 3. Bazzi WM, Sjoberg DD, Feuerstein MA, Maschino A, Verma S, Bernstein M, O’Brien MF, Jang T, Lowrance W, Motzer RJ, Russo P. Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol. 2015;193:1911–6. 4. Sanchez-Gastaldo A, Kempf E, Gonzalez Del Alba A, Duran I. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat Rev. 2017;60:77–89. 5. Patil S, Manola J, Elson P, Negrier S, Escudier B, Eisen T, Atkins M, Bukowski R, Motzer RJ. Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials. J Urol. 2012;188:2095–100.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|